title: Progress in the proxifan class: heterocyclic congeners as novel potent and selective histamine H(3)-receptor antagonists.
abstract: Histamine H(3) receptors are critically involved in the pathophysiology of several disorders of the central nervous system (CNS). Among other families of H(3)-receptor ligands, the proxifan class has recently been described to contain numerous potent histamine H(3)-receptor antagonists, e.g. ciproxifan or imoproxifan. In the present study, we report on the design of novel heterocyclic proxifan analogues and their antagonist potencies at histamine H(3) receptors. The new compounds were tested for in vitro and in vivo H(3)-receptor antagonist potencies in different species as well as for H(3)-receptor selectivity vs. H(1) and H(2) receptors. In vitro, all compounds investigated proved to be potent H(3)-receptor antagonists in the rat as well as in the guinea-pig. In addition, they showed good to high oral CNS potency in vivo in mice. Especially, oxadiazole derivatives 24-26 displayed nanomolar antagonist activity in vitro and high potency in vivo (ED(50)=0.47-0.57 mg/kg). The results show that the additional heteroaromatic moieties might act as bioisosteres of the ketone or oxime moieties of ciproxifan or imoproxifan, respectively, and might cause divergent pharmacokinetic properties. Thus, these novel H(3)-receptor antagonists are interesting leads for further development.
authors: Institut für Pharmazie, Freie Universität Berlin, Königin-Luise-Strasse 2+4, 14195, Germany. sveng@schunet.pharmazie.fu-berlin.de
authors: Sven
authors: S
authors: Grassmann
authors: Bassem
authors: B
authors: Sadek
authors: Xavier
authors: X
authors: Ligneau
authors: Sigurd
authors: S
authors: Elz
authors: C Robin
authors: CR
authors: Ganellin
authors: Jean-Michel
authors: JM
authors: Arrang
authors: Jean-Charles
authors: JC
authors: Schwartz
authors: Holger
authors: H
authors: Stark
authors: Walter
authors: W
authors: Schunack
mesh_terms: D000818:Animals; D002540:Cerebral Cortex / Q000187:drug effects / Q000378:metabolism; D006168:Guinea Pigs; D006571:Heterocyclic Compounds / Q000138:chemical synthesis* / Q000494:pharmacology*; D006633:Histamine Antagonists / Q000138:chemical synthesis* / Q000494:pharmacology*; D006636:Histamine Release / Q000187:drug effects; D007082:Ileum / Q000187:drug effects; D007093:Imidazoles / Q000138:chemical synthesis* / Q000494:pharmacology*; D066298:In Vitro Techniques; D007202:Indicators and Reagents; D051379:Mice; D009130:Muscle, Smooth / Q000187:drug effects; D051381:Rats; D011969:Receptors, Histamine H1 / Q000187:drug effects; D011970:Receptors, Histamine H2 / Q000187:drug effects; D018100:Receptors, Histamine H3 / Q000187:drug effects*; D013329:Structure-Activity Relationship; D013574:Synaptosomes / Q000187:drug effects / Q000378:metabolism
chemical_list: D006571:Heterocyclic Compounds; D006633:Histamine Antagonists; D007093:Imidazoles; D007202:Indicators and Reagents; D011969:Receptors, Histamine H1; D011970:Receptors, Histamine H2; D018100:Receptors, Histamine H3; C417965:proxyfan